Morgan Stanley adds Amazon.com as Top Pick
A group of entities related to Casdin Capital, including Casdin Partners Master Fund, L.P., Casdin Capital, LLC, and Casdin Partners GP, LLC, reported purchasing shares of Standard Biotools Inc. (NASDAQ:LAB) on September 3rd and 4th, 2025. The purchases totaled $635,750. The company, currently valued at approximately $497 million, trades near its InvestingPro Fair Value, with a strong financial health score of 2.67 out of 5.
The transactions involved the acquisition of 250,000 shares on September 3rd at a weighted average price ranging from $1.2414 to $1.2765, and another 250,000 shares on September 4th at a weighted average price ranging from $1.2621 to $1.2930. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a robust current ratio of 5.16x.
Following these transactions, Casdin Partners Master Fund, L.P. directly owns 60,775,000 shares. Eli Casdin directly owns 2,901,062 shares. Casdin Private Growth Equity Fund II, L.P. directly owns 13,939,637 shares and Casdin Private Growth Equity Fund, L.P. directly owns 2,744,219 shares.
Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
In other recent news, Standard BioTools Inc. reported a revenue beat in its first earnings report following the divestiture of SomaLogic, though it missed bottom-line expectations. The company has set core revenue guidance between $78 million and $83 million. Following the sale of its SomaLogic business to Illumina for up to $425 million, Standard BioTools plans to consolidate its research and development operations, incurring approximately $3.6 million in restructuring costs. This restructuring involves moving operations from South San Francisco to Singapore and includes a reduction in the U.S. workforce.
KeyBanc maintains a Sector Weight rating on Standard BioTools, noting the company’s challenging near-term outlook but highlighting potential for future acquisitions. In a strategic move, Standard BioTools’ SomaScan 11K Assay was selected by Precision Health Research, Singapore, for a study analyzing 100,000 plasma samples. Additionally, the company announced restricted stock unit awards for its CEO and CFO, with increased bonus targets for the CFO. These developments reflect ongoing shifts within the company as it navigates a period of transformation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.